Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX
by Zacks Equity Research
LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX are included in this Analyst Blog.
HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery
by Zacks Equity Research
HCA Healthcare's (HCA) ESR program remains on track to attract more patients to choose HCA's healthcare facilities for undergoing surgeries.
Syneos Health (SYNH) to Enhance Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) owing to strong international growth.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left
by Nalak Das
we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
by Zacks Equity Research
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise
by Zacks Equity Research
IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Hologic's (HOLX) Panther Utilization Rises, Supply Issue Ails
by Zacks Equity Research
Hologic (HOLX) registers procedural volumes return in GYN Surgical as well as acceleration from its new business lines.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) led by strategic collaborations and noteworthy product launches.
Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
by Zacks Equity Research
With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.
Thermo Fisher (TMO) Expands Global Footprint With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility in China is a strategic addition to the company's global pharma services network.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.
After Plunging 10.9% in 4 Weeks, Here's Why the Trend Might Reverse for Shockwave Medical (SWAV)
by Zacks Equity Research
Shockwave Medical (SWAV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AmerisourceBergen (ABC) to Repurchase Common Stock Worth $200M
by Zacks Equity Research
AmerisourceBergen (ABC) announces a share repurchase worth $200 million in concurrence with the sale of its shares by one of its shareholders, Walgreens Boots Alliance, under Rule 144.
Boston Scientific's (BSX) New Buyout to Expand Global Presence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.
LabCorp (LH) Gains on Innovation Amid Currency Headwinds
by Zacks Equity Research
LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to help match patients with critical and potentially life-changing treatments for cancer and other diseases.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.
Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.
Cooper Companies (COO) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.
LabCorp's (LH) New APH Lab to Expand Global Capabilities
by Zacks Equity Research
LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.
Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome
by Zacks Equity Research
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.